EBM & Clinical Trials
Remdesivir Shows Modest Improvement in Moderate COVID-19 Patients
2 Jun, 2020 | 04:59h | UTC- Gilead’s remdesivir shows modest improvement in moderate COVID-19 patients – Reuters
- Expert reaction to press release announcing results of stage 3 trial of Gilead’s antiviral remdesivir in moderate patients – Science Media Centre
- Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show – STAT
An Open Letter to Mehra et al and The Lancet
1 Jun, 2020 | 03:58h | UTCAn open letter to Mehra et al and The Lancet – Zenodo
See also: Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere – The Scientist AND A Study Out of Thin Air – Medicine (Un)Censored
Perspective: Will Evidence-Based Medicine Survive COVID-19?
1 Jun, 2020 | 03:56h | UTCWill Evidence-Based Medicine Survive COVID-19? – Boston Review
Opinion: Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic
29 May, 2020 | 03:27h | UTCUsing Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic – JAMA
Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity
29 May, 2020 | 03:26h | UTCConducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity – JAMA
Review of Trials Currently Testing Treatment and Prevention of COVID-19
28 May, 2020 | 09:48h | UTC
WHO: Revealing the Toll of COVID-19 – A Technical Package for Rapid Mortality Surveillance and Epidemic Response
27 May, 2020 | 02:48h | UTC
Related Commentary on Twitter
Countries need real-time mortality data for an effective #COVID19 response.
WHO together with @VitalStrat & @AfricaCDC released a new technical package on rapid mortality surveillance https://t.co/NeIZFNW774#WorldHealthData pic.twitter.com/5HcDjfXxBD
— World Health Organization (WHO) (@WHO) May 25, 2020
Perspective: The Totality of the Evidence, by Dr. John Ioannidis
27 May, 2020 | 02:29h | UTCThe Totality of the Evidence – Boston Review
See other interesting perspectives from the Boston Review: Models v. Evidence AND Good Science Is Good Science
“Given what we know now, it is reasonable to consider alternatives to population-wide lockdown, even as we focus on protecting those most at risk and support health care systems to care for patients who are sick.”
Preprinting a Pandemic: The Role of Preprints in the COVID-19 Pandemic
27 May, 2020 | 02:25h | UTCPreprinting a pandemic: the role of preprints in the COVID-19 pandemic – bioRxiv
Reasons to Worry Less About the Explosion of Preprints
27 May, 2020 | 02:24h | UTCReasons to Worry Less About the Explosion of Preprints – Absolutely Maybe Blog
Perspective: “Here’s What Needs to Happen Before We Can All Get Vaccinated for COVID-19”
26 May, 2020 | 09:45h | UTCHere’s what needs to happen before we can all get vaccinated for COVID-19 – CBC
Impact of COVID-19 on Oncology Clinical Trials
26 May, 2020 | 09:40h | UTCImpact of COVID-19 on oncology clinical trials – Nature Reviews Drug Discovery
Commentary: More Than 200 International Cancer Trials Suspended Due to COVID-19 – Medscape (free registration required)
WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial Due to Safety Concerns
26 May, 2020 | 09:35h | UTCSee also: WHO halts hydroxychloroquine trial for coronavirus amid safety fears – The Guardian AND WHO Halts Hydroxychloroquine Trial Over Safety Concerns – NPR
Editorial – SARS-CoV2 Vaccines: Slow is Fast
25 May, 2020 | 01:54h | UTCSARS-CoV2 vaccines: Slow is fast – Science
Open Access: How COVID-19 will Change the Way Research Findings are Shared
22 May, 2020 | 04:48h | UTCOpen access: how COVID-19 will change the way research findings are shared – Wellcome
Related: Plan S: Making Full and Immediate Open Access a Reality AND UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject) AND PLOS and the University of California announce open access publishing agreement – PLOS Blogs AND The war to free science – Vox (free) AND WHO Joins Coalition for Free Digital Access to Health Research
A Critical Look at A Preprint Inferring the Covid-19 Infection Fatality Rate
21 May, 2020 | 09:21h | UTCA Critical Look at A Preprint Inferring the Covid-19 Infection Fatality Rate – by Hilda Bastian
Original Preprint: The infection fatality rate of COVID-19 inferred from seroprevalence data – medRxiv
Open-access Science Funders Announce Price Transparency Rules for Publishers
19 May, 2020 | 04:12h | UTCOpen-access science funders announce price transparency rules for publishers – Science
Original Guidance: Plan S Price Transparency Frameworks: guidance & requirements – Plan S
News Release: cOAlition S announces price transparency requirements – Plan S
Related: Plan S: Making Full and Immediate Open Access a Reality AND UC Terminates Subscriptions with World’s Largest Scientific Publisher in Push for Open Access (several resources on the subject) AND PLOS and the University of California announce open access publishing agreement – PLOS Blogs AND The war to free science – Vox (free) AND WHO Joins Coalition for Free Digital Access to Health Research
Wrong but Useful — What Covid-19 Epidemiologic Models Can and Cannot Tell Us
18 May, 2020 | 01:48h | UTCRelated: Modelling the pandemic – The BMJ AND Predictive Mathematical Models of the COVID-19 Pandemic (several commentaries on the subject)
Podcast: Finding Reliable Information about Covid-19
15 May, 2020 | 03:36h | UTCAudio Interview: Finding Reliable Information about Covid-19 – New England Journal of Medicine
Editorial: Waste in Covid-19 Research
13 May, 2020 | 02:17h | UTCWaste in covid-19 research – The BMJ
Related Landmark Paper from the Author: Avoidable waste in the production and reporting of research evidence – The Lancet (free registration required)
Related Commentary on Twitter
"A deluge of poor quality research is sabotaging an effective evidence based response" say @PaulGlasziou, Sharon Sanders and @Tammy_Hoffmann https://t.co/jvx8FQxQCo
— The BMJ (@bmj_latest) May 12, 2020
Study Commentary – Virus Wars: Return of Lopinavir/Ritonavir (Along with Ribavirin and Interferon)
13 May, 2020 | 02:12h | UTCVirus Wars: Return of Lopinavir/Ritonavir (along with ribavirin and interferon) – PulmCrit
Original Article: Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial (study and commentaries)
Richard Lehman’s Covid-19 Reviews—11 May 2020
12 May, 2020 | 03:22h | UTCRichard Lehman’s Covid-19 Reviews, 11 May 2020 – The BMJ Opinion
In this weekly round-up, Richard Lehman looks at a personal selection of articles of relevance to clinicians dealing with covid-19
Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation
12 May, 2020 | 03:08h | UTCRelated: Medical Reversals in Family Practice: A Review – Current Therapeutic Research AND Meta-Research: A Comprehensive Review of Randomized Trials Leading to “Medical Reversals” in Three Medical Journals
COVID-19 Research in Brief: 2 May to 8 May, 2020
11 May, 2020 | 00:24h | UTCCOVID-19 Research in Brief: 2 May to 8 May, 2020 – Nature Medicine
Perspective: When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?
11 May, 2020 | 00:23h | UTCWhen Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials? – JAMA (via @AndersPerner)
Author Interview: When Should Physicians Act on Non–Statistically Significant Results From Clinical Trials?
“The burden of proof required to do “more” should probably be higher than to do “less,” particularly if doing “more” is likely to increase overall health care costs.”